Phase 1/2 Study of the Timing and Efficacy of 3 mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols.

Patel, Amol; Pathak, Abhishek; Sarin, Arti; Shelly, Divya; Ranjan, Richa; Singh, Arashdeep; Kala, Tripti; Pv, Babitha

Patel, Amol; Pathak, Abhishek; Sarin, Arti; Shelly, Divya; Ranjan, Richa; Singh, Arashdeep; Kala, Tripti; Pv, Babitha.

Afiliación

Patel A; Indian Naval Hospital Ship, Asvini, Mumbai, Maharashtra, India.
Pathak A; Command Hospital, Kolkata, West Bengal, India.
Sarin A; Western Naval Command, Mumbai, Maharashtra, India.
Shelly D; Indian Naval Hospital Ship, Asvini, Mumbai, Maharashtra, India.
Ranjan R; Command Hospital, Kolkata, West Bengal, India.
Singh A; Indian Naval Hospital Ship, Asvini, Mumbai, Maharashtra, India.
Kala T; Day Care Chemotherapy Centre, INHS, Asvini, Mumbai, Maharashtra, India.
Pv B; Day Care Chemotherapy Centre, INHS, Asvini, Mumbai, Maharashtra, India.

South Asian J Cancer ; 12(3): 238-244, 2023 Jul.

Article en En | MEDLINE | ID: mdl-38047054

Palabras clave

3 mg; Indian patients; dose dense protocol; pegylated GCSF; phase 2 study

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: South Asian J Cancer Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google